Artivion (NYSE:AORT) Insider John Davis Sells 6,563 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 6,563 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.86, for a total transaction of $300,979.18. Following the transaction, the insider owned 198,842 shares of the company’s stock, valued at approximately $9,118,894.12. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Price Performance

NYSE:AORT traded down $0.30 during trading hours on Friday, hitting $45.29. 178,693 shares of the stock were exchanged, compared to its average volume of 433,364. The company has a market cap of $2.15 billion, a P/E ratio of -107.83 and a beta of 1.65. The firm’s fifty day moving average price is $42.64 and its 200 day moving average price is $36.03. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.04. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Artivion

Institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd lifted its holdings in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the last quarter. MCF Advisors LLC lifted its stake in Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the period. State of Wyoming acquired a new stake in shares of Artivion in the third quarter valued at $80,000. Finally, Quadrant Capital Group LLC purchased a new stake in shares of Artivion in the 3rd quarter valued at $92,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on AORT shares. Citigroup reiterated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Oppenheimer reissued an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Stifel Nicolaus raised their target price on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group upped their price objective on shares of Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.